或forglipron,一个口服小分子GLP-1受体激动剂,在早期的2型糖尿病
Julio Rosenstock1, Stanley Hsia2, Luis Nevarez Ruiz3
1Velocity Clinical Research Center at Medical City Dallas, Dallas.
The New England journal of medicine
|June 22, 2025
概括
新型口服GLP-1受体激动剂Orforglipron有效降低了2型糖尿病成年人的A1C. 这项研究表明,在40周的时间里,血糖控制和体重管理显著改善.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 奥尔福格利是一种实验性口服的非类GLP-1受体激动剂.
- 它正在开发用于2型糖尿病和体重管理.
- 需要进一步的疗效和安全性数据.
研究的目的:
- 为了评估orforglipron在患有2型糖尿病的成年人中的疗效和安全性.
- 为了确定血糖控制和减肥的最佳剂量.
主要方法:
- 第三阶段,双盲,安慰剂对照试验.
- 559名患有2型糖尿病的参与者 (HbA1c 7.0-9.5%,BMI ≥23.0) 被随机分配给orforglipron (3,12或36毫克) 或安慰剂,每天服用一次,持续40周.
- 主要终点:从基线到第40周HbA1c的变化. 二级终点:体重的百分比变化.
主要成果:
- 与安慰剂相比,Orforglipron在所有剂量中显著降低了HbA1c (平均降低-1.24至-1.48个百分点 vs. -0.41).
- 在40周的平均HbA1c在6.5-6.7%与或forglipron.
- 奥福格利也导致了显著的体重减轻 (-4.5%至-7.6%与安慰剂的-1.7%相比).
- 最常见的不良事件是剂量升级期间轻度至中度的胃肠道问题;没有报告严重的低血糖症.
结论:
- 在40周内,Orforglipron在降低早期2型糖尿病的成年人HbA1c水平方面表现出显著的有效性.
- 药物一般耐受性很好,胃肠道事件是最常见的副作用.
- 在治疗2型糖尿病方面,Orforglipron是一个有前途的口服治疗选择.
相关概念视频
Glucagon-like Receptor Agonists
435
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
435
Oral Hypoglycemic Agents: Glinides
274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Oral Hypoglycemic Agents: Biguanides and Glitazones
310
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
310
Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
276
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
276
Oral Hypoglycemic Agents: Sulfonylureas
353
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
353


